Chloroquine retinopathy may progress long after drug cessation

Article

Despite treatment, chloroquine retinopathy may continue to progress long after drug cessation, according to a study published on-line by the British Journal of Ophthalmology. Further, disease progression may be accompanied by cystoid macular oedema, epiretinal membrane formation and peripheral involvement.

Despite treatment, chloroquine retinopathy may continue to progress long after drug cessation, according to a study published on-line by the British Journal of Ophthalmology. Further, disease progression may be accompanied by cystoid macular oedema, epiretinal membrane formation and peripheral involvement.

In order to assess the progression of morphological alterations in chloroquine or hydroxychloroquine retinopathy after drug cessation, researchers included 11 women, who underwent clinical exam, high-resolution OCT with spectral-domain OCT, fundus autofluorescence (FAF), near-infrared autofluorescence (NIA) and ultra-wide-angle autofluorescence (UW-FAF) 2.1 to 7.1 years after drug cessation.

Two patients with very limited parafoveal retinopathy had no progression within 3 years, but visual acuity in the remaining nine patients deteriorated, and the progression of retinal degeneration could be documented. FAF, UW-FAF, and NIA changes included increase of affected area, or a regional increase or decrease of FAF or NIA intensity. SD-OCT changes included reduction of retinal thickness, increased area of photoreceptor or retinal pigment epithelial loss, development or increase of cystoid macular oedema in four women, or development of epiretinal membranes in five women. Therapy of cystoid macular oedema had limited benefit.

To access this study, visit the journal's website here.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.